Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan.
Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
Hum Gene Ther. 2022 Aug;33(15-16):801-809. doi: 10.1089/hum.2022.005.
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by steroidogenic enzymes containing monogenetic defects. Most steroidogenic enzymes are cytochrome P450 groups that can be categorized as microsomal P450s, including 21-hydroxylase and 17α-hydroxylase/17,20 lyase, and mitochondrial P450s, including 11β-hydroxylase. It has been shown that ectopic administration of ameliorates steroid metabolism in 21-hydroxylase-deficient mice. However, the effectiveness of this approach for mitochondrial P450 has not yet been evaluated. In this study, primary fibroblasts from patients with 21-hydroxylase deficiency (CYP21A2D) ( = 4), 17α-hydroxylase/17,20 lyase deficiency (CYP17A1D) ( = 1), and 11β-hydroxylase deficiency (CYP11B1D) ( = 1) were infected with adeno-associated virus type 2 (AAV2) vectors. Steroidogenic enzymatic activity was not detected in the AAV2-infected CYP11B1D fibroblasts. Induced pluripotent stem cells (iPSCs) of CYP11B1D were established and differentiated into adrenocortical cells by induction of the gene. Adrenocortical cells established from iPSCs of CYP11B1D (CYP11B1D-iPSCs) were infected with an AAV type 9 (AAV9) vector containing and exhibited 11β-hydroxylase activity. For an evaluation, we knocked out in mice by using the CRISPR/Cas9 method. Direct injection of -containing AAV9 vectors into the adrenal gland of -deficient mice significantly reduced serum 11-deoxycorticosterone/corticosterone ratios at 4 weeks after injection and the effect was prolonged for up to 12 months. This study indicated that CYP11B1D could be ameliorated by gene induction in the adrenal glands, which suggests that a defective-enzyme-dependent therapeutic strategy for CAH would be required. Defects in microsomal P450, including CYP21A2D and CYP17A1D, can be treated with extra-adrenal gene induction. However, defects in mitochondrial P450, as represented by CYP11B1D, may require adrenal gene induction.
先天性肾上腺皮质增生症 (CAH) 是一种常染色体隐性遗传病,由含有单基因缺陷的类固醇生成酶引起。大多数类固醇生成酶是细胞色素 P450 组,可以分为微粒体 P450 组,包括 21-羟化酶和 17α-羟化酶/17,20 裂解酶,以及线粒体 P450 组,包括 11β-羟化酶。已经表明,异位给予可以改善 21-羟化酶缺陷型小鼠的类固醇代谢。然而,这种方法对线粒体 P450 的有效性尚未得到评估。在这项研究中,从 21-羟化酶缺陷型 (CYP21A2D) 患者的原代成纤维细胞 (n = 4)、17α-羟化酶/17,20 裂解酶缺陷型 (CYP17A1D) (n = 1) 和 11β-羟化酶缺陷型 (CYP11B1D) (n = 1) 中感染腺相关病毒 2 型 (AAV2) 载体。在 AAV2 感染的 CYP11B1D 成纤维细胞中未检测到类固醇生成酶活性。通过诱导 基因,建立了 CYP11B1D 的诱导多能干细胞 (iPSC),并分化为肾上腺皮质细胞。从 CYP11B1D 的 iPSC 建立的肾上腺皮质细胞 (CYP11B1D-iPSC) 被含有 的 AAV 类型 9 (AAV9) 载体感染,并表现出 11β-羟化酶活性。为了进行评估,我们使用 CRISPR/Cas9 方法在小鼠中敲除了 基因。将含有 的 AAV9 载体直接注射到 -缺陷型小鼠的肾上腺中,可显著降低注射后 4 周时血清 11-脱氧皮质酮/皮质酮比值,且效果可延长至 12 个月。这项研究表明,通过肾上腺中的基因诱导可以改善 CYP11B1D,这表明需要针对 CAH 的缺陷酶依赖性治疗策略。包括 CYP21A2D 和 CYP17A1D 在内的微粒体 P450 的缺陷可以通过肾上腺外的基因诱导来治疗。然而,以 CYP11B1D 为代表的线粒体 P450 的缺陷可能需要肾上腺基因诱导。